A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs. Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer - Clinical Trial - Takeaways - MDSpire

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs. Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer - Clinical Trial

This is a randomized, phase 3, multicenter trial designed to determine if induction weekly chemotherapy, when added to standard concurrent chemoradiotherapy and immunotherapy, for locally advanced cervical cancers can improve disease control and cure rate. The outcome for this study will be assessed over the first 2-3 years following completion of the therapy to which the patient is randomized. 

  • By

  • July 26, 2026

  • 3 min

Share

  • 1

    This phase 3 trial investigates the addition of induction chemotherapy to standard chemoradiotherapy and immunotherapy for cervical cancer.

  • 2

    The study aims to assess disease control and cure rates over 2-3 years following the completion of randomized therapy.

  • 3

    Eligible participants must have pathologically confirmed locally advanced cervical cancer with specific T and N classifications.

  • 4

    Induction chemotherapy may enhance tumor immunogenicity and reduce tumor burden prior to concurrent chemoradiation.

  • 5

    Exploratory analyses will include collection of tumor tissue and blood samples to study immune and molecular biomarkers.

Original Source(s)

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs. Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer - Clinical Trial

  • by

  • July 26, 2026

Related Content

Multimodal breast cancer diagnosis using feature fusion and deep learning

CT-derived myosteatosis as a predictor of postoperative outcomes in esophagogastric cancer surgery: a systematic review

Correction: Plasticity and antigen presentation by group 3 innate lymphoid cells in colorectal cancer